Clinical study on cilostazol combined with pancreatic kininogenase in treatment of LEADDP
10.3760/cma.j.issn.1674-6090.2011.03.019
- VernacularTitle:西洛他唑联合胰激肽原酶治疗2型糖尿病下肢血管病变临床研究
- Author:
Zhiming ZHANG
- Publication Type:Journal Article
- Keywords:
Type 2 diabetes mellitus;
Low extremity arterial disease;
Cilostazol;
Pancreatic kininogenase
- From:
Journal of Endocrine Surgery
2011;05(3):197-199,211
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare clinical effects between cilostazol(CLT)alone and cilostazol combined with pancreatic kininogenase(PK)on lower extremity arterial disease in diabetic patient(LEADDP).Methods Patients with LEADDP were randomly divided into 2 groups:single medication group or the control group(53 cases)and combination group or the treatment group(53 cases).Sugar-reducing medicines were given before and after treatment to keep a steady blood glucose level.The control group took CLT orally 100 mg each time,twice a day.Besides receiving the same dose of CLT,the treatment group took 120 tablet of PK on an empty stomach,three times a day,with the duration of 3 months.Clinical symptoms,ankle/brachial index(ABI),blood rheology,nailfold microcirculation,intimal medial thickness(IMT)and plaque thickness were compared between the 2 groups after treatment.Results Symptoms in both groups improved after treatment.ABI was elevated significantly compared to that before treatment(P<0.05)and the change was more obvious in combination group.The difference of ABI after treatment between the 2 groups had statistical significance(P<0.05).IMT of the right foot dorsal artery,and left and right posterior tibial artery increased significantly compared to that before treatment(P<0.05).Plaque thickness decreased compared to that before treatment(P<0.01)and the difference between before and after treatment in combination group was significantly greater than that in single medication group(P<0.05).Conclusion Cilostazol combined with pancreatic kininogenase has better clinical effects than cilostazol alone in treatment of patients with LEADDP.
